(Q2)Mar 31, 2024 | (Q1)Dec 31, 2023 | (FY)Sep 30, 2023 | (Q4)Sep 30, 2023 | (Q3)Jun 30, 2023 | (Q2)Mar 31, 2023 | (Q1)Dec 31, 2022 | (FY)Sep 30, 2022 | (Q4)Sep 30, 2022 | (Q3)Jun 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -8.29%-651.35K | 18.24%-815.37K | -33.44%-4.7M | -2.47%-1.43M | -167.19%-1.67M | 17.63%-601.47K | -29.40%-997.33K | -119.86%-3.52M | -229.05%-1.4M | -191.08%-625.24K |
Net income from continuing operations | 48.00%-888.69K | 57.44%-862.12K | -53.98%-11.59M | -148.50%-6.3M | 10.37%-1.55M | 22.40%-1.71M | -91.90%-2.03M | 4.65%-7.53M | 0.67%-2.54M | 39.04%-1.73M |
Operating gains losses | -68,572.50%-465.61K | 739.16%87.55K | 722.44%305.92K | 645.92%275.07K | 650.17%19.74K | 151.95%680 | 12,520.24%10.43K | -1,603.95%-49.15K | -3,154.97%-50.39K | 175.50%2.63K |
Depreciation and amortization | -49.48%41.84K | 61.44%134.22K | 151.97%411.64K | 126.15%157.36K | 69.98%88.33K | 295.10%82.81K | 298.58%83.14K | 3,127.32%163.37K | 1,701.71%69.58K | 12,892.00%51.97K |
Asset impairment expenditure | ---- | ---- | --5.27M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Remuneration paid in stock | ---- | ---- | --157.21K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Unrealized gains and losses of investment securities | --0 | --0 | 67.31%-28.32K | 91.73%-6.51K | -120.17%-15.88K | 641.60%175.2K | -64.29%-181.13K | -127.50%-86.63K | -225.00%-78.75K | -23.08%78.75K |
Remuneration paid in stock | -97.65%11.21K | -95.87%51.09K | -46.97%1.83M | -97.63%8.93K | -88.41%107.71K | -67.77%476.46K | 85.39%1.24M | -36.50%3.45M | -75.37%376.99K | -61.13%929.14K |
Other non cashItems | 998.85%373.99K | 25.25%-30.76K | -151.57%-463.27K | ---337.19K | ---43.33K | ---41.61K | ---41.15K | --898.34K | ---- | ---- |
Change In working capital | -33.38%275.91K | -142.45%-195.35K | -58.93%-590.68K | -768.03%-650.96K | -695.87%-273.29K | 940.22%414.14K | 72.52%-80.57K | -437.80%-371.66K | -8.43%-74.99K | -65.89%45.87K |
-Change in receivables | 1,144.13%794.25K | -244.62%-641.31K | -49.45%-588.17K | -6.42%-405.63K | 832.19%79.62K | -411.59%-76.07K | -1,496.44%-186.09K | -4,936.01%-393.56K | -12,441.86%-381.15K | -253.86%-10.87K |
-Change in prepaid assets | 2,233.56%211.16K | 74.65%157.62K | -51.03%-192.56K | 108.12%16.01K | -768.86%-307.87K | 112.82%9.05K | -4.32%90.25K | 31.35%-127.5K | -38.00%-197.29K | -40.78%46.03K |
-Change in payables and accrued expense | -251.61%-729.5K | 1,788.31%288.35K | 27.20%190.04K | -151.91%-261.35K | -520.57%-45.04K | 1,230.98%481.16K | 103.81%15.27K | 20.06%149.4K | 555.21%503.44K | -82.09%10.71K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -8.29%-651.35K | 18.24%-815.37K | -33.44%-4.7M | -2.47%-1.43M | -167.19%-1.67M | 17.63%-601.47K | -29.40%-997.33K | -119.86%-3.52M | -229.05%-1.4M | -191.08%-625.24K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | 28.97%-2.97M | 42.97%-3.15M | 5.48%-16.88M | 63.66%-1.37M | 19.51%-5.81M | 32.11%-4.18M | -671.70%-5.52M | -326.75%-17.86M | -82.64%-3.78M | -372.39%-7.21M |
Capital expenditure reported | ---- | ---- | 6.47%-9.44M | -2.54%-1.77M | ---- | ---- | ---- | ---10.09M | ---1.73M | ---- |
Net PPE purchase and sale | -154.70%-2.57M | 42.97%-3.15M | --8.09K | --3.39M | 12.24%3.16M | 59.56%-1.01M | -1,641.63%-5.52M | --0 | --0 | 284.12%2.81M |
Net business purchase and sale | ---- | ---- | ---3.31M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Net investment purchase and sale | ---- | ---- | --285.89K | --97.9K | --71.62K | ---- | ---- | --0 | --0 | --0 |
Net other investing changes | ---- | ---- | 43.03%-4.43M | 111.16%228.35K | 17.73%-1.37M | ---- | ---- | -108.81%-7.77M | ---2.05M | ---1.66M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | 28.97%-2.97M | 42.97%-3.15M | 5.48%-16.88M | 63.66%-1.37M | 19.51%-5.81M | 32.11%-4.18M | -671.70%-5.52M | -326.75%-17.86M | -82.64%-3.78M | -372.39%-7.21M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 0 | 0 | 206.33%21.43M | -99.80%10.96K | -150.10%-313.27K | 2,278.49%21.68M | -22.40%54.12K | -68.65%7M | 1,809.82%5.39M | -96.32%625.33K |
Net common stock issuance | ---- | ---- | 290.19%21.15M | -99.80%10.96K | ---313.27K | ---- | ---- | 35.50%5.42M | --5.42M | --0 |
Proceeds from stock option exercised by employees | --0 | --0 | -82.17%280.92K | --0 | --0 | -75.12%226.8K | -22.40%54.12K | -91.40%1.58M | -92.94%19.92K | -96.63%574.33K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | --0 | --0 | 206.33%21.43M | -99.80%10.96K | -150.10%-313.27K | 2,278.49%21.68M | -22.40%54.12K | -68.65%7M | 1,809.82%5.39M | -96.32%625.33K |
Net cash flow | ||||||||||
Beginning cash position | 41.35%8.15M | -1.13%12.09M | -54.05%12.23M | 23.81%14.87M | 17.88%22.66M | -77.13%5.76M | -54.05%12.23M | 163.85%26.61M | -58.32%12.01M | 41.86%19.23M |
Current changes in cash | -121.41%-3.62M | 38.68%-3.97M | 98.97%-148.23K | -1,386.79%-2.79M | -7.99%-7.79M | 382.98%16.9M | -356.46%-6.47M | -187.03%-14.38M | 109.82%216.94K | -147.23%-7.21M |
Effect of exchange rate changes | ---523.63K | --19.15K | --10.33K | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
End cash Position | -82.34%4M | 41.35%8.15M | -1.13%12.09M | -1.13%12.09M | 23.81%14.87M | 17.88%22.66M | -77.13%5.76M | -54.05%12.23M | -54.05%12.23M | -58.32%12.01M |
Free cash from | -100.00%-3.22M | 39.19%-3.97M | -3.86%-14.14M | 105.54%173.11K | -0.07%-6.18M | 50.06%-1.61M | -499.44%-6.52M | -558.66%-13.61M | -354.56%-3.13M | -254.55%-6.17M |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.